Regeneron Pharmaceuticals’ (REGN) “Hold” Rating Reiterated at BTIG Research

BTIG Research restated their hold rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report published on Tuesday.

Other equities research analysts also recently issued research reports about the stock. BMO Capital Markets set a $444.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a hold rating in a research note on Monday, November 27th. Citigroup downgraded shares of Regeneron Pharmaceuticals from a buy rating to a neutral rating and dropped their target price for the stock from $480.00 to $380.00 in a research report on Friday, December 1st. Cowen reissued a hold rating and issued a $450.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, February 7th. Piper Jaffray Companies reissued a buy rating and issued a $540.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, November 13th. Finally, Jefferies Group reissued a hold rating and issued a $380.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, February 8th. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of Hold and an average price target of $463.19.

Shares of Regeneron Pharmaceuticals (REGN) opened at $333.18 on Tuesday. Regeneron Pharmaceuticals has a one year low of $313.53 and a one year high of $543.55. The stock has a market cap of $35,529.00, a price-to-earnings ratio of 23.93, a P/E/G ratio of 1.41 and a beta of 1.47. The company has a current ratio of 3.82, a quick ratio of 3.18 and a debt-to-equity ratio of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter in the previous year, the firm posted $3.04 EPS. The firm’s quarterly revenue was up 28.9% on a year-over-year basis. analysts expect that Regeneron Pharmaceuticals will post 14.13 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $325.60, for a total transaction of $325,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 10.80% of the company’s stock.

A number of institutional investors have recently bought and sold shares of REGN. Ark Investment Management LLC boosted its stake in Regeneron Pharmaceuticals by 78.8% during the 2nd quarter. Ark Investment Management LLC now owns 1,234 shares of the biopharmaceutical company’s stock valued at $606,000 after purchasing an additional 544 shares during the period. Virtu KCG Holdings LLC acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $206,000. Cubist Systematic Strategies LLC boosted its stake in Regeneron Pharmaceuticals by 176.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 671 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 428 shares during the period. Raymond James Financial Services Advisors Inc. boosted its stake in Regeneron Pharmaceuticals by 13.3% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 3,212 shares of the biopharmaceutical company’s stock valued at $1,578,000 after purchasing an additional 378 shares during the period. Finally, WINTON GROUP Ltd acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $713,000. 65.89% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://stocknewstimes.com/2018/02/16/regeneron-pharmaceuticals-regn-hold-rating-reiterated-at-btig-research.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply